(Reuters) - A panel of independent experts to the U.S. health regulator on Friday voted against the use of Novo Nordisk's weekly insulin in patients with type 1 diabetes due to risks of low blood sugar. The Food and Drug Administration's panel vote...
Related Keywords
Bengaluru , Karnataka , India , Denmark , Danish , Tasim Zahid , Shailesh Kuber , Sriparna Roy , Novo Nordisk , European Union , Reuters , Drug Administration , Mariam Sunny ,
vimarsana.com © 2020. All Rights Reserved.